# ARYx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aryx-therapeutics

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.aryx.com
- Total disclosed funding: $110M
- Latest round: Series E (Jan 25, 2006)
- Investors on record: 11

## About

ARYx Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions aimed at improving patient outcomes in various medical conditions.Founded in 1997 and headquartered in Fremont, US, ARYx Therapeutics Inc. specializes in biotechnology. It has undergone significant changes in its business strategy over time. The company has engaged in 8 investment deals and recently raised USD 6.3 mn in a VENTURE DEBT round from Lighthouse Capital Partners, contributing to a total of USD 0.35 mn raised. The founder's information is not specified.ARYx Therapeutics Inc. is dedicated to developing therapeutic solutions that address unmet medical needs. Its portfolio includes advanced drug formulations targeting specific health issues, with a focus on enhancing patient treatment efficacy. The company primarily serves the healthcare sector, catering to diverse medical applications and patient demographics.The company's revenue for the most recent year, 2009, was reported at USD 0.00, with an EBITDA reflecting a loss of USD 29,751,000. This indicates challenges in maintaining revenue streams during that period.ARYx Therapeutics Inc. has ceased operations, and as such, no future growth plans or new product launches are currently being pursued. The company's last funding round was designated to support ongoing operations, but no further information is available regarding future initiatives.

## Funding rounds

- Series E, Jan 25, 2006, $30M — OrbiMed Advisors, Montreux Equity Partners, Scottish Widows Investment Partnership, Ascent Biomedical Ventures, Icon Ventures, Phase4 Partners, MPM BioImpact, Merlin.dk, Novel Bioventures
- Series D, Jun 2, 2004, $55M — OrbiMed Advisors, Montreux Equity Partners, Scottish Widows Investment Partnership, Icon Ventures, Phase4 Partners, MPM BioImpact, ATEL Capital Group, Merlin.dk, ITOCHU Technology Ventures, Novel Bioventures
- Series C, Jul 2, 2002, $25M — OrbiMed Advisors, MPM BioImpact, Merlin.dk

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D, Series E
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C, Series D, Series E
- Merlin.dk — Series C, Series D, Series E
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series D, Series E
- Scottish Widows Investment Partnership (https://capitalatlas.ai/funds/scottish-widows-investment-partnership) — Series D, Series E
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series D, Series E
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series D, Series E
- ATEL Capital Group (https://capitalatlas.ai/funds/atel-capital-group) — Series D
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series D
- Novel Bioventures — Series D, Series E
- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series E